About
About China Isotope & Radiation Corporation
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. The company operates through five segments: Nuclear Medicines; Radioactive Source Products; Irradiation; Nuclear Medical Equipment and Related Services; and Other Businesses. The Nuclear Medicines segment engages in research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test diagnostic kits, test analyzers, and other products. The Radioactive Source Products segment sells medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, pharmaceuticals, cosmetics, and food for sterilization, and provides design, manufacturing, and installation of gamma ray irradiation facilities and related technical services. The Nuclear Medical Equipment and Related Services segment sells nuclear medical equipment and provides related maintenance services. The Other Businesses segment provides trade services for nuclear technology industry applications, medical product applications, technical services, and sales of medical devices. This segment also offers independent clinical laboratory services for nuclear technology industry applications and medical product applications; and provides radioactive sources, medical nuclides, imported radiopharmaceuticals, nuclear instruments and devices, medical equipment and other products. The company was incorporated in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation operates as a subsidiary of China National Nuclear Corporation.
Visit company website
5 years, 5 months ago
China Isotope & Radiation Corporation is currently in a long term uptrend where the price is trading 12.4% above its 200 day moving average.
From a valuation standpoint, the stock is 98.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
China Isotope & Radiation Corporation's total revenue rose by 18.1% to $3B since the same quarter in the previous year.
Its net income has dropped by 21.8% to $142M since the same quarter in the previous year.
Finally, its free cash flow grew by 133.4% to $95M since the same quarter in the previous year.
Based on the above factors, China Isotope & Radiation Corporation gets an overall score of 4/5.